A gastroenterology research group is conducting a randomized controlled trial to evaluate a new monoclonal antibody against standard therapy for moderate-to-severe Crohn's disease. Four hundred patients are randomized equally into two independent treatment arms. The primary endpoint compares the proportion of patients achieving clinical remission at week 12, categorized as either 'achieved' or 'not achieved', between the two groups. A secondary endpoint compares the absolute reduction in the Crohn's Disease Activity Index (CDAI), a continuous numerical score, between the two treatment groups. Preliminary data analysis reveals that the CDAI reduction scores in both treatment arms are highly skewed and significantly violate the assumption of normality.
Which of the following statistical tests are appropriate for analyzing the endpoints in this study? (Select all that apply)
- Pearson's chi-square test to analyze the difference in clinical remission rates between the two groupsAnswer
- Mann-Whitney U test to analyze the difference in absolute CDAI reduction between the two groupsAnswer
- CUnpaired Student t-test to analyze the difference in absolute CDAI reduction between the two groups
- DMcNemar test to analyze the difference in clinical remission rates between the two groups
- EWilcoxon signed-rank test to analyze the difference in absolute CDAI reduction between the two groups